Last Updated: November 16, 2026

Details for Patent: 9,211,295

« Back to Dashboard


Summary for Patent: 9,211,295
Title:17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Abstract:17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity are provided, along with methods of using these compounds and processes for their preparation.
Inventor(s):Mauro Ajani, Luigi Moro
Assignee: Cassiopea SpA
Application Number:US14/474,765
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

US Patent 9,211,295: Claim Scope, Patent Landscape, and Generic-Entry Analysis for Cortexolone 17α-Propionate

US Patent 9,211,295 protects pharmaceutical use of cortexolone 17α-propionate, also known as clascoterone, in topical and certain broader pharmaceutical formulations for acne, alopecia, hirsutism, and seborrhea. The strongest practical coverage is directed to topical products containing clascoterone, particularly creams, gels, and liposomal formulations. The patent does not claim clascoterone as a chemical compound itself.

The claims divide into two groups:

  1. Claims 1-12 cover formulations.
  2. Claims 13-26 cover methods for treating hirsutism and seborrhea.

The patent is relevant to Winlevi, the FDA-approved clascoterone cream marketed by Cosmo Pharmaceuticals through its U.S. commercial arrangements. FDA approved Winlevi 1% cream for the topical treatment of acne vulgaris in patients 12 years and older in August 2020.[1]

What drug and active ingredient does US Patent 9,211,295 cover?

The claimed active ingredient is 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione, commonly called cortexolone 17α-propionate or clascoterone.

Attribute Detail
Active ingredient Cortexolone 17α-propionate
Common name Clascoterone
Drug class Topical androgen-receptor antagonist
Commercial product Winlevi
Approved dosage form 1% topical cream
FDA indication Acne vulgaris
Patent number U.S. 9,211,295
Patent type Formulation and method-of-treatment patent
Chemical-compound claim No
Primary commercial relevance Topical clascoterone formulations and therapeutic use

Clascoterone is converted in the skin to cortexolone and is designed to inhibit androgen-receptor signaling locally. The claimed molecule is structurally distinct from corticosteroids such as hydrocortisone, despite sharing the steroid nucleus.

What are the independent claims of US Patent 9,211,295?

The patent contains three commercially important independent claim structures.

Claim 1: Pharmaceutical formulation

Claim 1 covers:

  • a formulation for acne, alopecia, hirsutism, or seborrhea;
  • an effective amount of clascoterone;
  • suitability for topical application; and
  • a pharmaceutically acceptable carrier.

The claim is broad at the dosage-form level. It does not require a particular concentration, excipient, particle size, delivery system, or manufacturing process.

A product may fall within claim 1 if it contains the claimed active ingredient in a topical pharmaceutical formulation with a pharmaceutically acceptable carrier and is labeled or technically suitable for one of the listed conditions.

Claim 13: Treatment of hirsutism

Claim 13 covers administering an effective amount of clascoterone to a patient requiring treatment for hirsutism.

The independent claim does not expressly require topical administration. Dependent claims narrow the method to topical use and topical dosage forms.

This structure creates a potentially broad method claim, but enforcement would require proof that the accused product is administered for hirsutism and that the use falls within the claim's treatment limitations.

Claim 20: Treatment of seborrhea

Claim 20 covers administering an effective amount of clascoterone to treat seborrhea.

As with claim 13, the independent claim does not expressly require topical administration. Claims 21-26 narrow the method to topical treatment and specified formulation types.

How do claims 1-12 protect topical clascoterone formulations?

Claims 1-12 form a descending formulation hierarchy.

Claims Scope
1 Topical clascoterone formulation for acne, alopecia, hirsutism, or seborrhea
2 Cream formulation
3 Gel formulation
4 Liposomal emulsion or suspension
5 Cream containing at least one listed excipient
6 Cream containing cetyl alcohol
7 Cetyl alcohol plus glycerol monostearate
8 Claims 6-7 plus liquid paraffin
9 Claims 6-8 plus propylene glycol
10 Claims 6-9 plus disodium mono-oleo-amide sulfosuccinate
11 Claims 6-10 plus citric acid monohydrate
12 Claims 6-11 plus water

Claim 1 is the principal broad formulation claim. Claims 2-4 create alternative dosage-form branches. Claims 5-12 progressively narrow the cream branch by requiring specific excipients.

The dependent claims use an open-ended formulation structure inherited from claim 1. A formulation containing additional excipients could still fall within the claims if it contains the required ingredients and otherwise meets the limitations.

What formulations are protected by claims 5-12?

Claims 5-12 are directed to a defined cream composition.

The full combination in claim 12 includes:

  • clascoterone;
  • cetyl alcohol;
  • glycerol monostearate;
  • liquid paraffin;
  • propylene glycol;
  • disodium mono-oleo-amide sulfosuccinate;
  • citric acid monohydrate; and
  • water.

The claims do not state quantitative ranges for these excipients. They also do not expressly require a 1% concentration of clascoterone. As a result, infringement analysis would depend on the claim construction of terms such as "effective amount," "cream," "pharmaceutically acceptable carrier," and "suitable for topical application."

A generic or follow-on product could avoid claims 6-12 by omitting one or more required excipients. That strategy would not necessarily avoid claim 1 or claim 2, because claim 1 does not require the listed excipient package and claim 2 broadly covers a cream.

Formulation design-around exposure

Product design Likely claim exposure
Clascoterone cream with a conventional carrier Potential claim 1 and claim 2 exposure
Clascoterone gel Potential claim 1 and claim 3 exposure
Clascoterone liposomal formulation Potential claim 1 and claim 4 exposure
Cream omitting cetyl alcohol Potentially avoids claims 6-12, but not necessarily claims 1-2
Cream using a different emulsifier system Potentially avoids claims 5-12, but not necessarily claims 1-2
Non-topical clascoterone product for hirsutism Potential claim 13 exposure
Non-topical clascoterone product for seborrhea Potential claim 20 exposure
Topical clascoterone for acne only Formulation claims remain relevant even though acne is not separately recited in claims 13-26

What do claims 13-19 protect for hirsutism?

Claims 13-19 protect a treatment sequence for hirsutism:

  • claim 13: administering clascoterone;
  • claim 14: topical application;
  • claim 15: use in a topical formulation;
  • claim 16: use with a pharmaceutically acceptable carrier;
  • claim 17: cream;
  • claim 18: gel;
  • claim 19: liposomal emulsion or suspension.

The hirsutism claims cover the active ingredient and treatment purpose rather than a particular concentration or excipient system. A product label expressly directing use for hirsutism would create greater method-of-use exposure than a product labeled solely for acne.

Inducement risk could also arise from promotional materials, physician instructions, clinical protocols, or other evidence showing an intent to encourage a claimed hirsutism use. A product's composition alone would not establish infringement of the hirsutism method claims without the required treatment or inducement facts.

What do claims 20-26 protect for seborrhea?

Claims 20-26 mirror the hirsutism claim structure for seborrhea:

  • claim 20: administering clascoterone;
  • claim 21: topical application;
  • claim 22: topical formulation;
  • claim 23: pharmaceutically acceptable carrier;
  • claim 24: cream;
  • claim 25: gel;
  • claim 26: liposomal emulsion or suspension.

The claims could be relevant to future clascoterone products for seborrheic dermatitis, seborrhea, or related androgen-responsive skin conditions, depending on the scope assigned to "seborrhea" and the product's labeling and use.

Does US Patent 9,211,295 protect acne and alopecia treatment methods?

Not directly through the method claims reproduced here.

Claims 1-12 identify acne and alopecia as conditions for which the formulation is intended. Claims 13-26, however, recite treatment methods only for hirsutism and seborrhea.

That distinction matters:

  • A topical clascoterone product for acne may implicate claims 1-12 through its formulation.
  • The supplied claims do not contain a standalone method claim expressly directed to acne.
  • The supplied claims do not contain a standalone method claim expressly directed to alopecia.
  • Acne and alopecia remain relevant because they appear in claim 1's intended therapeutic scope.

A court could evaluate whether the condition language in claim 1 is limiting and whether product labeling, technical characteristics, or marketing materials establish that the formulation is "for" one of the recited conditions.

How broad is the patent's claim coverage?

The patent has meaningful breadth at the formulation level but narrower breadth at the excipient level.

Broadest practical protection

Claim 1 is the most commercially important claim because it does not require:

  • a cream;
  • a gel;
  • a liposomal carrier;
  • a particular excipient;
  • a specific clascoterone concentration;
  • a specific release profile; or
  • a specified manufacturing process.

The principal required elements are the active ingredient, topical suitability, a pharmaceutically acceptable carrier, and one of four stated treatment purposes.

Narrower protection

Claims 5-12 are materially narrower because they require specific cream excipients. They may provide fallback protection against products using the claimed excipient architecture, but they are easier to design around than claim 1.

Claims 13 and 20 are broad in route because the independent claims do not expressly require topical administration. Their practical reach is limited by the need to prove treatment of the specified condition.

What patent does not claim?

Based on the supplied claims, US 9,211,295 does not expressly claim:

  • the clascoterone molecule as a new chemical entity;
  • a particular 1% concentration;
  • a specific dosing frequency;
  • a specific application amount;
  • a particular container or applicator;
  • a manufacturing process;
  • a crystalline or polymorphic form;
  • a particle-size distribution;
  • a transdermal patch;
  • a foam;
  • a shampoo;
  • a spray;
  • a specific pharmacokinetic profile; or
  • a specific clinical outcome.

This distinction is important for freedom-to-operate analysis. A product can avoid the listed excipient claims while still implicating the broad formulation claim or separate later patents directed to concentration, vehicle, stability, manufacturing, or clinical use.

What is the patent landscape around Winlevi and clascoterone?

The clascoterone patent estate is expected to include multiple patent families rather than a single blocking patent. The relevant categories are:

Patent category Potential subject matter
Active ingredient Cortexolone 17α-propionate and related steroid compounds
Therapeutic use Acne, alopecia, hirsutism, seborrhea, androgen-responsive disorders
Formulation Creams, gels, emulsions, suspensions, liposomes
Commercial formulation Vehicle composition, stability, skin delivery, preservative system
Manufacturing Synthesis, purification, crystallization, scale-up
Regulatory protection FDA product exclusivity and Orange Book-listed patents
Pediatric protection Pediatric exclusivity, if granted
International rights European, Japanese, Canadian and other national counterparts

US 9,211,295 should therefore be treated as one layer of the clascoterone estate. It is particularly relevant to formulation and certain therapeutic-use scenarios, but it should not be assumed to represent the entire U.S. blocking position for Winlevi.

What is the Orange Book status of US Patent 9,211,295?

A definitive Orange Book determination requires the current FDA Orange Book listing for the approved Winlevi product and its applicable patent-use codes. The patent's relevance cannot be established from the claim text alone.

For regulatory strategy, the following questions control:

  1. Is US 9,211,295 listed against the approved Winlevi NDA?
  2. Which patent-use codes are assigned?
  3. Does the listing cover acne, formulation, or another approved use?
  4. Is the patent listed as an active patent or marked expired?
  5. Does the NDA sponsor have other formulation or method patents listed?
  6. Are any listed patents subject to pediatric exclusivity or patent-term adjustment?

The Orange Book, FDA-approved labeling, and the patent's current USPTO record are the controlling sources for this analysis.[1,2]

When does US Patent 9,211,295 lose exclusivity?

The ordinary U.S. patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[3]

The patent's operative expiration date should be taken from the current USPTO patent record and any applicable FDA patent-term-extension record. The grant date alone does not determine expiration.

Patent expiry also does not eliminate all regulatory barriers. A generic applicant may face:

  • other unexpired formulation patents;
  • method-of-use patents;
  • Orange Book certification obligations;
  • FDA exclusivity;
  • manufacturing patents;
  • trade-secret barriers;
  • product-development requirements; and
  • potential state-law or commercial launch constraints.

Are there Paragraph IV risks for a clascoterone generic?

A generic applicant seeking approval before expiration of listed patents could submit an Abbreviated New Drug Application with a Paragraph IV certification against patents it believes are invalid, unenforceable, or not infringed.[4]

For a topical clascoterone product, the principal Paragraph IV theories could include:

  • non-infringement based on a different vehicle;
  • omission of listed excipients;
  • absence of an indication for hirsutism or seborrhea;
  • lack of topical suitability under the asserted claim construction;
  • invalidity based on anticipation;
  • obviousness of the formulation;
  • indefiniteness of terms such as "effective amount" or "suitable for topical application"; and
  • lack of written description or enablement for the asserted scope.

The most important distinction is between an ANDA product and its labeling. A generic seeking approval only for acne may have a stronger carve-out position against method claims directed to hirsutism or seborrhea, but it could remain exposed to formulation claims that include acne.

Which companies are challenging the clascoterone patent estate?

The supplied claim text does not establish the existence, identity, or status of a Paragraph IV challenger, ANDA litigation, inter partes review, post-grant review, or settlement agreement.

A reliable competitive assessment must distinguish among:

  • an ANDA filing;
  • a Paragraph IV notice letter;
  • a patent-infringement complaint;
  • a declaratory-judgment action;
  • an inter partes review petition;
  • a district-court settlement; and
  • a commercial launch.

These events have different legal and commercial consequences. A company identified in a patent database as an assignee, licensee, or applicant is not necessarily a litigation challenger.

How strong is the patent estate for clascoterone?

US 9,211,295 has moderate-to-strong practical value for products that use clascoterone in a conventional topical dosage form and are marketed for one of the listed conditions.

Strength factors

  • The active ingredient is narrowly and clearly identified.
  • Claim 1 reaches multiple topical dosage forms.
  • Claim 1 does not require the detailed excipient combination.
  • The claim expressly includes acne, the approved Winlevi indication.
  • Claims 13 and 20 extend to hirsutism and seborrhea treatment.
  • Dependent claims provide fallback coverage for cream, gel, and liposomal products.

Vulnerability factors

  • The patent does not claim the molecule itself.
  • A formulation-only claim can be designed around at the vehicle level.
  • The excipient claims are narrow.
  • The method claims require proof of treatment for specific conditions.
  • Terms such as "effective amount" and "suitable for topical application" may generate claim-construction disputes.
  • Separate patents may control the commercial product after this patent expires.

The strongest claim is likely claim 1 from a commercial infringement perspective. Claims 5-12 provide narrower fallback positions but are less likely to block every alternative vehicle.

What generic launch scenarios exist?

Scenario Commercial outcome
Generic uses a materially different topical vehicle May avoid narrow excipient claims but remains exposed to claim 1
Generic uses a cream with the claimed excipients High risk under claims 5-12 if all limitations are met
Generic seeks acne-only labeling May reduce exposure to hirsutism and seborrhea method claims
Generic uses a gel Claim 3 and claim 1 remain relevant
Generic uses a liposomal formulation Claim 4 and claim 1 remain relevant
Generic launches after all relevant patents expire Lowest patent risk, subject to regulatory approval
Generic challenges listed patents under Paragraph IV Possible early launch, subject to litigation and 30-month stay rules
Generic uses a non-topical route May avoid topical formulation claims but could implicate claims 13 or 20

What manufacturing and intellectual-property barriers remain?

The patent claims supplied do not cover a manufacturing process. A competitor could therefore face a separate freedom-to-operate review for:

  • starting-material selection;
  • steroid synthesis;
  • esterification of cortexolone;
  • purification;
  • impurity control;
  • polymorphism;
  • particle engineering;
  • cream homogenization;
  • filling and packaging; and
  • stability control.

A generic applicant may be able to manufacture clascoterone without infringing US 9,211,295 while still encountering separate process or formulation patents. Trade secrets involving manufacturing parameters may also affect commercial replication without appearing in patent claims.

Key Takeaways

  • US 9,211,295 covers clascoterone formulations and specified therapeutic uses, not clascoterone as a chemical compound.
  • Claim 1 is the broadest formulation claim and reaches topical creams, gels, and other carrier-based products for acne, alopecia, hirsutism, or seborrhea.
  • Claims 5-12 protect progressively narrower cream compositions containing specified excipients.
  • Claims 13-19 target hirsutism treatment, while claims 20-26 target seborrhea treatment.
  • The supplied claims do not contain standalone method claims for acne or alopecia.
  • A generic may design around the narrow excipient claims, but avoiding claim 1 requires a stronger formulation or intended-use position.
  • Orange Book status, current patent expiration, Paragraph IV activity, litigation, and settlements cannot be determined from the claim text alone.
  • The patent should be analyzed as one component of the broader U.S. clascoterone estate covering formulation, use, manufacturing, and regulatory exclusivity.

FAQs

Does US Patent 9,211,295 claim Winlevi by brand name?

No. The claims identify the active ingredient, cortexolone 17α-propionate, and specified formulations and uses. They do not use the Winlevi brand name.

Can a clascoterone gel avoid the patent?

Not necessarily. Claim 3 expressly covers a gel, and claim 1 broadly covers a topical clascoterone formulation with a pharmaceutically acceptable carrier.

Can removing cetyl alcohol avoid all claims?

Removing cetyl alcohol may avoid claim 6 and the claims depending from it. It would not necessarily avoid claims 1-4, which do not require cetyl alcohol.

Does an acne-only generic avoid the hirsutism and seborrhea claims?

It may reduce exposure to those method claims because the product would not be labeled for the claimed conditions. It would not necessarily avoid the formulation claims, which expressly include acne.

Is a non-topical clascoterone product outside the patent?

A non-topical product may avoid the topical formulation claims, but claims 13 and 20 do not expressly require topical administration in their independent form. The applicable claim scope would depend on the route, indication, and treatment facts.

References

  1. U.S. Food and Drug Administration. (2020). FDA approves new treatment for acne. FDA.
  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
  3. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension. USPTO.
  4. U.S. Food and Drug Administration. (n.d.). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,211,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,211,295

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2001A1762Aug 10, 2001

International Family Members for US Patent 9,211,295

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 289318 ⤷  Start Trial
Australia 2002328956 ⤷  Start Trial
Canada 2454675 ⤷  Start Trial
China 1246328 ⤷  Start Trial
China 1541220 ⤷  Start Trial
Germany 60203013 ⤷  Start Trial
Denmark 1421099 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.